{"name":"Mylan Inc.","slug":"mylan-inc","ticker":"","exchange":"","domain":"mylan.com","description":"Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a \"Global Center\" in Canonsburg, Pennsylvania, US.","hq":"Canonsburg","founded":0,"employees":"N/A","ceo":"Heather Bresch","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":6796110000,"revenueGrowth":10.9,"grossMargin":0,"rdSpend":581800000,"netIncome":640850000,"cash":15886600000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2012"},"revenueBreakdown":[],"timeline":[{"date":"1959-01-01","label":"Soma first approved","drug":"Soma","drugSlug":"carisoprodol","type":"approval","sentiment":"positive"},{"date":"1978-01-01","label":"Rimso-50 first approved","drug":"Rimso-50","drugSlug":"dimethyl-sulfoxide","type":"approval","sentiment":"positive"},{"date":"1989-01-01","label":"Paraplatin first approved","drug":"Paraplatin","drugSlug":"carboplatin","type":"approval","sentiment":"positive"},{"date":"1993-01-01","label":"Felbatol first approved","drug":"Felbatol","drugSlug":"felbamate","type":"approval","sentiment":"positive"},{"date":"1994-01-01","label":"Cystagon first approved","drug":"Cystagon","drugSlug":"mercaptamine","type":"approval","sentiment":"positive"},{"date":"1996-01-01","label":"Denavir first approved","drug":"Denavir","drugSlug":"penciclovir","type":"approval","sentiment":"positive"},{"date":"2001-01-01","label":"Arixtra first approved","drug":"Arixtra","drugSlug":"fondaparinux","type":"approval","sentiment":"positive"},{"date":"2018-01-01","label":"Yupelri first approved","drug":"Yupelri","drugSlug":"revefenacin","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-12-31","label":"FULPHILA Phase 3 readout (Primary Mediastinal Large B-Cell Lymphoma)","drug":"FULPHILA","drugSlug":"pegfilgrastim-jmdb","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-03-01","label":"EFAVIRENZ, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE Phase 2 readout (Acquired Immune Deficiency Syndrome (AIDS), HIV Infections)","drug":"EFAVIRENZ, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE","drugSlug":"efavirenz-emtricitabine-and-tenofovir-alafenamide","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-09-30","label":"FULPHILA Phase 2 readout (Renal Pelvis and Ureter Urothelial Carcinoma)","drug":"FULPHILA","drugSlug":"pegfilgrastim-jmdb","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-07-01","label":"EFAVIRENZ, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE Phase 2 readout (HIV-1-infection)","drug":"EFAVIRENZ, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE","drugSlug":"efavirenz-emtricitabine-and-tenofovir-alafenamide","type":"phase3_readout","sentiment":"neutral"},{"date":"2032-03-23","label":"OGIVRI Phase 3 readout (Endometrial Cancer)","drug":"OGIVRI","drugSlug":"trastuzumab-dkst","type":"phase3_readout","sentiment":"neutral"},{"date":"2034-10-02","label":"OGIVRI Phase 3 readout (Breast Cancer)","drug":"OGIVRI","drugSlug":"trastuzumab-dkst","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":28,"colorKey":"immunology","drugs":[{"name":"Transdermal system containing progestin","genericName":"Transdermal system containing progestin","slug":"transdermal-system-containing-progestin","indication":"Contraception","status":"phase_3"},{"name":"Denavir","genericName":"PENCICLOVIR","slug":"penciclovir","indication":"Herpes labialis","status":"marketed"},{"name":"Dymista","genericName":"Dymista","slug":"dymista","indication":"Other","status":"marketed"},{"name":"EFAVIRENZ, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE","genericName":"EFAVIRENZ, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE","slug":"efavirenz-emtricitabine-and-tenofovir-alafenamide","indication":"Other","status":"marketed"},{"name":"Estradiol Vaginal Cream, 0.01%","genericName":"Estradiol Vaginal Cream, 0.01%","slug":"estradiol-vaginal-cream-0-01","indication":"Vaginal atrophy associated with menopause","status":"phase_3"},{"name":"Fexofenadine Tablets 180 mg","genericName":"Fexofenadine Tablets 180 mg","slug":"fexofenadine-tablets-180-mg","indication":"Other","status":"phase_1"},{"name":"TOBI® PODHALER®","genericName":"TOBI® PODHALER®","slug":"tobi-podhaler","indication":"Other","status":"marketed"},{"name":"Adoxa Tablets 150 mg","genericName":"Adoxa Tablets 150 mg","slug":"adoxa-tablets-150-mg","indication":"Other","status":"phase_1"},{"name":"Azithromycin Tablets 600 mg","genericName":"Azithromycin Tablets 600 mg","slug":"azithromycin-tablets-600-mg","indication":"Other","status":"phase_1"},{"name":"BALSALAZIDE DISODIUM CAPSULES, 750 MG","genericName":"BALSALAZIDE DISODIUM CAPSULES, 750 MG","slug":"balsalazide-disodium-capsules-750-mg","indication":"Other","status":"phase_1"},{"name":"Cystagon","genericName":"Mercaptamine","slug":"mercaptamine","indication":"Cystinosis","status":"marketed"},{"name":"Dilantin® Kapseals® 100 mg","genericName":"Dilantin® Kapseals® 100 mg","slug":"dilantin-kapseals-100-mg","indication":"Other","status":"phase_1"},{"name":"Estrace® 0.01% cream","genericName":"Estrace® 0.01% cream","slug":"estrace-0-01-cream","indication":"Atrophic vaginitis (vaginal atrophy) associated with menopause","status":"phase_3"},{"name":"HULIO","genericName":"ADALIMUMAB-FKJP","slug":"adalimumab-fkjp","indication":"Other","status":"marketed"},{"name":"Hercules","genericName":"Hercules","slug":"hercules","indication":"Other","status":"phase_1"},{"name":"Lipacreon","genericName":"Lipacreon","slug":"lipacreon","indication":"Other","status":"phase_2"},{"name":"MYL-1701P","genericName":"MYL-1701P","slug":"myl-1701p","indication":"Chemotherapy-induced neutropenia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy","status":"phase_3"},{"name":"Metoprolol Tartrate Tablets 25 mg","genericName":"Metoprolol Tartrate Tablets 25 mg","slug":"metoprolol-tartrate-tablets-25-mg","indication":"Other","status":"phase_1"},{"name":"Nisoldipine Extended-release Tablets, 30 mg","genericName":"Nisoldipine Extended-release Tablets, 30 mg","slug":"nisoldipine-extended-release-tablets-30-mg","indication":"Other","status":"phase_1"},{"name":"Ondansetron Orally Disintegrating Tablets 8 mg","genericName":"Ondansetron Orally Disintegrating Tablets 8 mg","slug":"ondansetron-orally-disintegrating-tablets-8-mg","indication":"Other","status":"phase_1"},{"name":"Oxybutynin Chloride Extended-Release Tablets, 15 mg","genericName":"Oxybutynin Chloride Extended-Release Tablets, 15 mg","slug":"oxybutynin-chloride-extended-release-tablets-15-mg","indication":"Other","status":"phase_1"},{"name":"Pioglitazone HCl Tablets 45 mg","genericName":"Pioglitazone HCl Tablets 45 mg","slug":"pioglitazone-hcl-tablets-45-mg","indication":"Other","status":"phase_1"},{"name":"Placebo inhalation solution QD","genericName":"Placebo inhalation solution QD","slug":"placebo-inhalation-solution-qd","indication":"Other","status":"phase_3"},{"name":"Rimso-50","genericName":"DIMETHYL SULFOXIDE","slug":"dimethyl-sulfoxide","indication":"Improvement of symptoms in patients with interstitial cystitis","status":"marketed"},{"name":"Sulfamylon® For 5 % Topical Solution","genericName":"Sulfamylon® For 5 % Topical Solution","slug":"sulfamylon-for-5-topical-solution","indication":"Adjunctive topical antimicrobial agent for second and third-degree burns","status":"marketed"},{"name":"Topamax® Sprinkle Capsules 25 mg","genericName":"Topamax® Sprinkle Capsules 25 mg","slug":"topamax-sprinkle-capsules-25-mg","indication":"Other","status":"phase_1"},{"name":"Topiramate Sprinkle Capsules 25 mg","genericName":"Topiramate Sprinkle Capsules 25 mg","slug":"topiramate-sprinkle-capsules-25-mg","indication":"Other","status":"phase_1"},{"name":"Valtrex® 1000 mg","genericName":"Valtrex® 1000 mg","slug":"valtrex-1000-mg","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"Paraplatin","genericName":"Carboplatin","slug":"carboplatin","indication":"Breast cancer","status":"marketed"},{"name":"OGIVRI","genericName":"TRASTUZUMAB-DKST","slug":"trastuzumab-dkst","indication":"HER2-positive carcinoma of breast","status":"marketed"},{"name":"Bevacizumab as Avastin","genericName":"Bevacizumab as Avastin","slug":"bevacizumab-as-avastin","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"Bevacizumab as MYL-1402O","genericName":"Bevacizumab as MYL-1402O","slug":"bevacizumab-as-myl-1402o","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"MYL- 1401O","genericName":"MYL- 1401O","slug":"myl-1401o","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"MYL-1401H","genericName":"MYL-1401H","slug":"myl-1401h","indication":"HER2-positive metastatic breast cancer","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"rare","drugs":[{"name":"FlexPen NovoLog®","genericName":"FlexPen NovoLog®","slug":"flexpen-novolog","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"MR-100A-01","genericName":"MR-100A-01","slug":"mr-100a-01","indication":"Type 2 diabetes","status":"phase_3"},{"name":"MYL-1601D Product","genericName":"MYL-1601D Product","slug":"myl-1601d-product","indication":"Type 2 diabetes","status":"phase_3"},{"name":"MYL-1701P, a proposed biosimilar to Eylea","genericName":"MYL-1701P, a proposed biosimilar to Eylea","slug":"myl-1701p-a-proposed-biosimilar-to-eylea","indication":"Neovascular (wet) age-related macular degeneration","status":"phase_3"},{"name":"Mylan's insulin glargine","genericName":"Mylan's insulin glargine","slug":"mylan-s-insulin-glargine","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"cardiovascular","drugs":[{"name":"TD-4208","genericName":"TD-4208","slug":"td-4208","indication":"Atrial fibrillation for stroke prevention","status":"phase_3"},{"name":"Arixtra","genericName":"FONDAPARINUX","slug":"fondaparinux","indication":"Deep venous thrombosis","status":"marketed"},{"name":"Nebivolol (NEB)","genericName":"Nebivolol (NEB)","slug":"nebivolol-neb","indication":"Hypertension","status":"marketed"},{"name":"Nebivolol and Atenolol","genericName":"Nebivolol and Atenolol","slug":"nebivolol-and-atenolol","indication":"Hypertension","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"neuroscience","drugs":[{"name":"Bethkis®","genericName":"Bethkis®","slug":"bethkis","indication":"Cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection","status":"marketed"},{"name":"Cayston®","genericName":"Cayston®","slug":"cayston","indication":"Cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection","status":"marketed"},{"name":"Topical Antimicrobial/Antifungal Medications","genericName":"Topical Antimicrobial/Antifungal Medications","slug":"topical-antimicrobial-antifungal-medications","indication":"Fungal skin infections (e.g., tinea pedis, tinea corporis, candidiasis)","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"ophthalmology","drugs":[{"name":"Placebo for Revefenacin","genericName":"Placebo for Revefenacin","slug":"placebo-for-revefenacin","indication":"Treatment of chronic cough due to idiopathic pulmonary fibrosis","status":"phase_3"},{"name":"Placebo for Spiriva Handihaler®","genericName":"Placebo for Spiriva Handihaler®","slug":"placebo-for-spiriva-handihaler","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_3"},{"name":"Yupelri","genericName":"REVEFENACIN","slug":"revefenacin","indication":"Chronic obstructive lung disease","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"respiratory","drugs":[{"name":"Felbatol","genericName":"FELBAMATE","slug":"felbamate","indication":"Epilepsy","status":"marketed"},{"name":"apomorphine HCl injection","genericName":"apomorphine HCl injection","slug":"apomorphine-hcl-injection","indication":"Treatment of advanced Parkinson's disease","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"metabolic","drugs":[{"name":"Humira® (Adalimumab)","genericName":"Humira® (Adalimumab)","slug":"humira-adalimumab","indication":"Rheumatoid arthritis","status":"marketed"},{"name":"MYL-1401A (Adalimumab)","genericName":"MYL-1401A (Adalimumab)","slug":"myl-1401a-adalimumab","indication":"Rheumatoid arthritis","status":"phase_3"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"FULPHILA","genericName":"PEGFILGRASTIM-JMDB","slug":"pegfilgrastim-jmdb","indication":"Allogeneic peripheral blood stem cell transplant","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"dermatology","drugs":[{"name":"Soma","genericName":"CARISOPRODOL","slug":"carisoprodol","indication":"Backache","status":"marketed"}]}],"pipeline":[{"name":"Paraplatin","genericName":"Carboplatin","slug":"carboplatin","phase":"marketed","mechanism":"Carboplatin produces predominantly interstrand DNA cross-links in a cell-cycle nonspecific manner.","indications":["Breast cancer","Malignant tumor of ovary"],"catalyst":""},{"name":"Transdermal system containing progestin","genericName":"Transdermal system containing progestin","slug":"transdermal-system-containing-progestin","phase":"phase_3","mechanism":"A transdermal progestin delivery system that releases the hormone through the skin to provide contraceptive and/or hormone replacement effects.","indications":["Contraception","Hormone replacement therapy (if applicable to specific formulation)"],"catalyst":""},{"name":"Denavir","genericName":"PENCICLOVIR","slug":"penciclovir","phase":"marketed","mechanism":"Denavir works by inhibiting the DNA polymerase enzyme of the herpes virus, preventing it from replicating and causing infection.","indications":["Herpes labialis"],"catalyst":""},{"name":"Dymista","genericName":"Dymista","slug":"dymista","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EFAVIRENZ, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE","genericName":"EFAVIRENZ, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE","slug":"efavirenz-emtricitabine-and-tenofovir-alafenamide","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Estradiol Vaginal Cream, 0.01%","genericName":"Estradiol Vaginal Cream, 0.01%","slug":"estradiol-vaginal-cream-0-01","phase":"phase_3","mechanism":"Estradiol vaginal cream delivers the hormone estrogen directly to vaginal tissues to relieve symptoms of vaginal atrophy and genitourinary syndrome of menopause.","indications":["Vaginal atrophy associated with menopause","Genitourinary syndrome of menopause (GSM)"],"catalyst":""},{"name":"Fexofenadine Tablets 180 mg","genericName":"Fexofenadine Tablets 180 mg","slug":"fexofenadine-tablets-180-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"OGIVRI","genericName":"TRASTUZUMAB-DKST","slug":"trastuzumab-dkst","phase":"marketed","mechanism":"Receptor tyrosine-protein kinase erbB-2","indications":["HER2-positive carcinoma of breast","HER2-positive colon cancer","HER2-positive rectal cancer","HER2-positive salivary gland tumors","Human epidermal growth factor 2 positive gastric cancer"],"catalyst":""},{"name":"TD-4208","genericName":"TD-4208","slug":"td-4208","phase":"phase_3","mechanism":"TD-4208 is a small molecule that acts as a selective inhibitor of the sodium-activated potassium channel, Nav1.5.","indications":["Atrial fibrillation for stroke prevention"],"catalyst":""},{"name":"TOBI® PODHALER®","genericName":"TOBI® PODHALER®","slug":"tobi-podhaler","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Adoxa Tablets 150 mg","genericName":"Adoxa Tablets 150 mg","slug":"adoxa-tablets-150-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Arixtra","genericName":"FONDAPARINUX","slug":"fondaparinux","phase":"marketed","mechanism":"Arixtra works by blocking the action of factor Xa, a protein involved in blood clotting.","indications":["Deep venous thrombosis","Prevention of deep vein thrombosis","Pulmonary thromboembolism"],"catalyst":""},{"name":"Azithromycin Tablets 600 mg","genericName":"Azithromycin Tablets 600 mg","slug":"azithromycin-tablets-600-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BALSALAZIDE DISODIUM CAPSULES, 750 MG","genericName":"BALSALAZIDE DISODIUM CAPSULES, 750 MG","slug":"balsalazide-disodium-capsules-750-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Bethkis®","genericName":"Bethkis®","slug":"bethkis","phase":"marketed","mechanism":"Bethkis is an inhaled antibiotic that delivers tobramycin directly to the lungs to kill Pseudomonas aeruginosa bacteria in cystic fibrosis patients.","indications":["Cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection"],"catalyst":""},{"name":"Bevacizumab as Avastin","genericName":"Bevacizumab as Avastin","slug":"bevacizumab-as-avastin","phase":"phase_3","mechanism":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.","indications":["Metastatic colorectal cancer","Metastatic non-small cell lung cancer","Metastatic breast cancer","Glioblastoma","Metastatic renal cell carcinoma"],"catalyst":""},{"name":"Bevacizumab as MYL-1402O","genericName":"Bevacizumab as MYL-1402O","slug":"bevacizumab-as-myl-1402o","phase":"phase_3","mechanism":"MYL-1402O is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.","indications":["Metastatic colorectal cancer","Metastatic non-small cell lung cancer","Metastatic breast cancer","Glioblastoma","Metastatic renal cell carcinoma"],"catalyst":""},{"name":"Cayston®","genericName":"Cayston®","slug":"cayston","phase":"marketed","mechanism":"Cayston is an inhaled antibiotic that disrupts bacterial biofilm formation and kills Pseudomonas aeruginosa in the lungs.","indications":["Cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection"],"catalyst":""},{"name":"Cystagon","genericName":"Mercaptamine","slug":"mercaptamine","phase":"marketed","mechanism":"Cystagon works by binding to cystine and forming a disulfide bond, effectively removing cystine from the body.","indications":["Cystinosis"],"catalyst":""},{"name":"Dilantin® Kapseals® 100 mg","genericName":"Dilantin® Kapseals® 100 mg","slug":"dilantin-kapseals-100-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Estrace® 0.01% cream","genericName":"Estrace® 0.01% cream","slug":"estrace-0-01-cream","phase":"phase_3","mechanism":"Estrace cream delivers estradiol, a natural estrogen, directly to vaginal and vulvar tissues to relieve symptoms of atrophic vaginitis and urogenital atrophy.","indications":["Atrophic vaginitis (vaginal atrophy) associated with menopause","Urogenital atrophy symptoms including vaginal dryness and dyspareunia"],"catalyst":""},{"name":"FULPHILA","genericName":"PEGFILGRASTIM-JMDB","slug":"pegfilgrastim-jmdb","phase":"marketed","mechanism":"Granulocyte colony-stimulating factor receptor","indications":["Allogeneic peripheral blood stem cell transplant","Chemotherapy-induced neutropenia"],"catalyst":""},{"name":"Felbatol","genericName":"FELBAMATE","slug":"felbamate","phase":"marketed","mechanism":"Felbamate's exact mechanism is unknown, but it shows anticonvulsant activity in various animal models and interacts with the NMDA receptor-ionophore complex.","indications":["Epilepsy","Lennox-Gastaut syndrome","Simple partial seizure"],"catalyst":""},{"name":"FlexPen NovoLog®","genericName":"FlexPen NovoLog®","slug":"flexpen-novolog","phase":"phase_3","mechanism":"NovoLog is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in cells.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"HULIO","genericName":"ADALIMUMAB-FKJP","slug":"adalimumab-fkjp","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Hercules","genericName":"Hercules","slug":"hercules","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Humira® (Adalimumab)","genericName":"Humira® (Adalimumab)","slug":"humira-adalimumab","phase":"marketed","mechanism":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine.","indications":["Rheumatoid arthritis","Psoriatic arthritis","Ankylosing spondylitis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"Lipacreon","genericName":"Lipacreon","slug":"lipacreon","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MR-100A-01","genericName":"MR-100A-01","slug":"mr-100a-01","phase":"phase_3","mechanism":"MR-100A-01 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"MYL- 1401O","genericName":"MYL- 1401O","slug":"myl-1401o","phase":"phase_3","mechanism":"MYL-1401O is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to prevent tumor angiogenesis.","indications":["Metastatic colorectal cancer","Non-squamous non-small cell lung cancer","Metastatic breast cancer","Renal cell carcinoma"],"catalyst":""},{"name":"MYL-1401A (Adalimumab)","genericName":"MYL-1401A (Adalimumab)","slug":"myl-1401a-adalimumab","phase":"phase_3","mechanism":"MYL-1401A is a biosimilar of adalimumab that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis","Ankylosing spondylitis","Psoriasis"],"catalyst":""},{"name":"MYL-1401H","genericName":"MYL-1401H","slug":"myl-1401h","phase":"phase_3","mechanism":"MYL-1401H is a biosimilar of trastuzumab that binds to HER2 receptors on cancer cells to inhibit their growth and promote immune-mediated cell death.","indications":["HER2-positive metastatic breast cancer","HER2-positive early-stage breast cancer (adjuvant/neoadjuvant setting)","HER2-positive metastatic gastric cancer"],"catalyst":""},{"name":"MYL-1601D Product","genericName":"MYL-1601D Product","slug":"myl-1601d-product","phase":"phase_3","mechanism":"MYL-1601D Product is a generic version of a medication that helps to lower blood sugar levels in people with type 2 diabetes.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"MYL-1701P","genericName":"MYL-1701P","slug":"myl-1701p","phase":"phase_3","mechanism":"MYL-1701P is a biosimilar of pegfilgrastim that stimulates neutrophil production to prevent chemotherapy-induced neutropenia.","indications":["Chemotherapy-induced neutropenia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy"],"catalyst":""},{"name":"MYL-1701P, a proposed biosimilar to Eylea","genericName":"MYL-1701P, a proposed biosimilar to Eylea","slug":"myl-1701p-a-proposed-biosimilar-to-eylea","phase":"phase_3","mechanism":"MYL-1701P is a biosimilar to aflibercept that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit pathological neovascularization in the eye.","indications":["Neovascular (wet) age-related macular degeneration","Retinal vein occlusion","Diabetic macular edema"],"catalyst":""},{"name":"Metoprolol Tartrate Tablets 25 mg","genericName":"Metoprolol Tartrate Tablets 25 mg","slug":"metoprolol-tartrate-tablets-25-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Mylan's insulin glargine","genericName":"Mylan's insulin glargine","slug":"mylan-s-insulin-glargine","phase":"phase_3","mechanism":"Insulin glargine is a long-acting insulin analog that mimics the action of human insulin to lower blood glucose levels.","indications":["Type 2 diabetes","Type 1 diabetes"],"catalyst":""},{"name":"Nebivolol (NEB)","genericName":"Nebivolol (NEB)","slug":"nebivolol-neb","phase":"marketed","mechanism":"Nebivolol is a selective beta-1 adrenergic receptor antagonist that also has vasodilatory properties through nitric oxide release.","indications":["Hypertension","Heart failure with reduced ejection fraction"],"catalyst":""},{"name":"Nebivolol and Atenolol","genericName":"Nebivolol and Atenolol","slug":"nebivolol-and-atenolol","phase":"phase_3","mechanism":"Nebivolol and atenolol are beta-blockers that reduce heart rate and blood pressure by blocking beta-adrenergic receptors on the heart and blood vessels.","indications":["Hypertension","Angina pectoris","Heart failure","Post-myocardial infarction management"],"catalyst":""},{"name":"Nisoldipine Extended-release Tablets, 30 mg","genericName":"Nisoldipine Extended-release Tablets, 30 mg","slug":"nisoldipine-extended-release-tablets-30-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ondansetron Orally Disintegrating Tablets 8 mg","genericName":"Ondansetron Orally Disintegrating Tablets 8 mg","slug":"ondansetron-orally-disintegrating-tablets-8-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Oxybutynin Chloride Extended-Release Tablets, 15 mg","genericName":"Oxybutynin Chloride Extended-Release Tablets, 15 mg","slug":"oxybutynin-chloride-extended-release-tablets-15-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Pioglitazone HCl Tablets 45 mg","genericName":"Pioglitazone HCl Tablets 45 mg","slug":"pioglitazone-hcl-tablets-45-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo for Revefenacin","genericName":"Placebo for Revefenacin","slug":"placebo-for-revefenacin","phase":"phase_3","mechanism":"This is a placebo, meaning it has no active pharmacological effect.","indications":["Treatment of chronic cough due to idiopathic pulmonary fibrosis"],"catalyst":""},{"name":"Placebo for Spiriva Handihaler®","genericName":"Placebo for Spiriva Handihaler®","slug":"placebo-for-spiriva-handihaler","phase":"phase_3","mechanism":"This is a placebo, meaning it has no active therapeutic effect.","indications":["Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Placebo inhalation solution QD","genericName":"Placebo inhalation solution QD","slug":"placebo-inhalation-solution-qd","phase":"phase_3","mechanism":"Placebo has no active pharmacological mechanism and produces therapeutic effects solely through the placebo effect.","indications":[],"catalyst":""},{"name":"Rimso-50","genericName":"DIMETHYL SULFOXIDE","slug":"dimethyl-sulfoxide","phase":"marketed","mechanism":"Small molecule","indications":["Improvement of symptoms in patients with interstitial cystitis","Ulcerative cystitis"],"catalyst":""},{"name":"Soma","genericName":"CARISOPRODOL","slug":"carisoprodol","phase":"marketed","mechanism":"Carisoprodol's mechanism for relieving acute musculoskeletal pain is unclear, but it involves altered interneuronal activity in the spinal cord and brain.","indications":["Backache","Muscle Spasm with Pain","Spasticity"],"catalyst":""},{"name":"Sulfamylon® For 5 % Topical Solution","genericName":"Sulfamylon® For 5 % Topical Solution","slug":"sulfamylon-for-5-topical-solution","phase":"marketed","mechanism":"Mafenide acetate inhibits bacterial folic acid synthesis by competing with para-aminobenzoic acid, thereby exerting broad-spectrum antimicrobial activity against burn wound pathogens.","indications":["Adjunctive topical antimicrobial agent for second and third-degree burns"],"catalyst":""},{"name":"Topamax® Sprinkle Capsules 25 mg","genericName":"Topamax® Sprinkle Capsules 25 mg","slug":"topamax-sprinkle-capsules-25-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Topical Antimicrobial/Antifungal Medications","genericName":"Topical Antimicrobial/Antifungal Medications","slug":"topical-antimicrobial-antifungal-medications","phase":"marketed","mechanism":"Topical antimicrobial and antifungal medications work by disrupting microbial cell membranes, inhibiting fungal cell wall synthesis, or interfering with microbial protein synthesis to eliminate or inhibit growth of bacteria and fungi on skin surfaces.","indications":["Fungal skin infections (e.g., tinea pedis, tinea corporis, candidiasis)","Bacterial skin infections","Mixed microbial skin infections"],"catalyst":""},{"name":"Topiramate Sprinkle Capsules 25 mg","genericName":"Topiramate Sprinkle Capsules 25 mg","slug":"topiramate-sprinkle-capsules-25-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Valtrex® 1000 mg","genericName":"Valtrex® 1000 mg","slug":"valtrex-1000-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Yupelri","genericName":"REVEFENACIN","slug":"revefenacin","phase":"marketed","mechanism":"Yupelri works by blocking the action of a chemical called acetylcholine, which stimulates the muscles in the airways, leading to bronchodilation.","indications":["Chronic obstructive lung disease"],"catalyst":""},{"name":"apomorphine HCl injection","genericName":"apomorphine HCl injection","slug":"apomorphine-hcl-injection","phase":"phase_3","mechanism":"Apomorphine HCl injection acts as a dopamine agonist, mimicking the action of dopamine in the brain.","indications":["Treatment of advanced Parkinson's disease","Treatment of 'off' episodes in patients with advanced Parkinson's disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPM083QTZjamg3THBPWHQwWTBxSXhJMkFXRzk2Uk5aVkxDb0lFQ1JTcmVBVjZzSDRVQ29QUUpLN3hPTmxEdldud0QzX0p2V3JEMUNKbDZzWFFrb3pJQjR2U0hkY3JTOTFaeGlHS3k2QTlMdFVmeWtHTTJGRlVteVJnRXJZSUZiY1VVTndCUjFQZTc3X19nY004RzN5VVZiem1PdzZldjllRlFnbzhVSXRiY0haOA?oc=5","date":"2026-04-01","type":"pipeline","source":"Yahoo Finance","summary":"Gemcitabine Hydrochloride Market Report 2026-2030 & 2035 Featuring Strategic Analysis of Fresenius Kabi, Eli Lilly and Company, Teva Pharma, Intas Pharma, Mylan and More - Yahoo Finance","headline":"Gemcitabine Hydrochloride Market Report 2026-2030 & 2035 Featuring Strategic Analysis of Fresenius Kabi, Eli Lilly and C","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQRGRqZE10blkzWTg1SnUtdFZpaUxFNzBxamV3akJnU2xEdlNnSGNKR0hCcHd6MWx6NTZsRmt6MzI0VERvUXF2OF9wX1ZOUEx1ckYxWWVIcTVhRm9FUmJlVDF0YWxhNWRycmZQUWZUOVN0MUI5NTk4aXBSdlRLbDNhX1l1eEVEOFU2LWF2STFSSGFfYW9RTk51QlM0Z3YxZVJid0VSSXRaWGdHemFla1ZGdk93?oc=5","date":"2026-02-07","type":"deal","source":"lupin.com","summary":"Lupin and Mylan Partner to Commercialize Enbrel® (Etanercept) Biosimilar - Lupin | Press Release - lupin.com","headline":"Lupin and Mylan Partner to Commercialize Enbrel® (Etanercept) Biosimilar - Lupin | Press Release","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNME4tM0RzY1c2dTdsN1pmYnplVW1MdlR0LWVIU0cyNG5ET3BuaGlOYWhmcFcxWHNOanZvcVlwMEN2RlhoeG9JTXUtT0JnUGtuWEQ2Y2NMVHpCYUZUZmxWcjBBMUJPUkVGaFZUc1BrRHNPMjdSSFBPa2xVd1VDTi1scHI3dHpVRU41c3lveC1PdEdLRXJqeUhBTkV2Z2tXZ0NKd2VOazA1a3pnWExjTXFoR3d5Yng0Sms3RlBN0gFyQVVfeXFMT3JNMEhrcHJaU0pYUEdXRDRPNXlKb2hfcUNCendlb0tJUmdxUjVURWV3WnQ4Vm9aZ0c1SFpDU0I3VWplUTZod0VTSWNfdjhpQW8wYTcyLUpENElnbWllTWRBME9MSnB1VDg4VWJlZTFGdkNB?oc=5","date":"2026-01-09","type":"patent","source":"Law360","summary":"Mylan, Aurobindo Must Face Generic Drug Price-Fixing Claims - Law360","headline":"Mylan, Aurobindo Must Face Generic Drug Price-Fixing Claims - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxOMXZwcUF2eWNSaHh2MVY4SlVxN25lSVQ4c2VQS3FzYndfdGk5aWFFUXdRZGtYT0IzeEJob3hUSXVZSjlpcU5uRWRnMXBOd3JVakxpRGpLUjdxYmJISGlXN2EwaWtmaGlKTGh6dGIxQXZRSDJ3c3dxckc0MEJNZ0tuMVk1R25aUVlndlVaSTM0X2FuZnBKelpUdmZtcWNCY3JIT0pyRW56aWFRcDdoTVhFaGtZNXNxWHBZQ0dhZWVVX3luNG9yUWxoS1Y1VXRBWFFfUE0wMw?oc=5","date":"2025-10-01","type":"trial","source":"Jones Day","summary":"Federal Circuit: When and How to Patent Around Clinical Trials - Jones Day","headline":"Federal Circuit: When and How to Patent Around Clinical Trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxQVHdleDB5YUJiWDJGczNoSDRWa0Rmb051YTBLd3hIM01BMGdrYVlSbUtrLWdQNnFfb29pbUlSOWw3SmpSanVXSzZkTTRzalpISlFfdktsUkk5bGp6dE9kVlg0WmxfVjhsdHYxUkN3MC1UUV9FdVlsWXI4MXJYYzhqWWhUVm5QMjl6M3FXS2pQOXJjcjJSYlBwY3ktV1hlYUhOUWtyVHplb2NfWUprNmZpcW5rZjZ3QTJQSDFQdjl6aGM0ckg2YmcwZE55aTNSRGtKaS1KUWJSdU56elFjVklfd2JhYmdjeUJzM3EzOUs4QzA0aHpGZnBYV01nRjY5QXEzYy12aEJ4bVNQMEswWjVqaWVPbXJOSl8zczZMbmJZMnFlRE96QlFpNkhqd1AtVkZaN0ExUm1DZmxxc28?oc=5","date":"2025-09-25","type":"patent","source":"Akin","summary":"Federal Circuit: The Term 'Clinically Proven Effective' Amount Does Not Impart Patentability Over Prior Art for Claims That Also Recite Specific Numerical Dosages - Akin","headline":"Federal Circuit: The Term 'Clinically Proven Effective' Amount Does Not Impart Patentability Over Prior Art for Claims T","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQV0s0YlFJcFBsazBwb09SZjFHVjdpSS1OX2hZbEFCU0lKeHEtTXdualV4V0RIVTZ2em5MSFB1YVh3T2RxU3BTNWhKTERPNUkzX3hJbURvaVNZNE5lcWpHNW5PVDZyZGZleW12ZGtEVDdiS0xIU19RY3RWQlJ3XzQyeVo5bFdwRXZJR1g5anZyT1M2M1FCNXNhU0dEMDg5SmdheFRoSzRB?oc=5","date":"2025-05-22","type":"regulatory","source":"Bloomberg Law News","summary":"Mylan Gets Final Approval of $73.5 Million EpiPen Antitrust Deal - Bloomberg Law News","headline":"Mylan Gets Final Approval of $73.5 Million EpiPen Antitrust Deal","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxNWFBESlJIRUFMLWtNS3ZJUnlxbk12SkR5MWNTSDVHZzhfemFBanhmelQwdk1oZ0ZxTEhOamEwUVNLcXFtQ0VYODlXeXB2aktaWXd0SkZXWG9HRTQwNjN5X3JFY21NMWpQMDd6RmNIZVZ4a3RrX1pzbVplVWYwTWxZay1Xb1hlaVo2bEpXM3dQazUxMGNDOVpZbDFoYW1ZSjcxd3A0b0FBay10bmUzR0lsTVUxdVF5WUhNa29rSVUyb2pZby1ZZFpJYllDX0RMN293ellqTXE0YTFJMWN6T2VQazQtbWlkWTBia3FBekN3?oc=5","date":"2025-05-06","type":"patent","source":"PR Newswire","summary":"Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations - PR Newswire","headline":"Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNNDY4enMwTkloNXFFbndHWEZlSWZRaDN6cHhIdjhWUzZtR1M3dWljQkxPYnhhdlFfb2x0NHdFRTc0YXhkTTdNc2JHSUY3Tjh4WTZMcmdkYU1kaG5WelRLNVZyYnVUQkZ3TVY2RzR2LUNjOXJodTZxMWpvWkx4TnRaVGdNbWVhNWg5cW42b3dFZUZvU25acHpqcjBmdEppdnhPSUNPS2FGc211VUpoNlRFeWhXUERSQjRDbTdMVVVR0gFaQVVfeXFMTkhSX3Ztel80eTB4VEpPSWFSWTdZTUVZeF8tOG9CeGVMT29mamlhZndfWDEzT0RhYUpSNWY5WlpyVEplUUpzMUZycndtR0IyWmRwSWxmVWtDMUVR?oc=5","date":"2025-05-06","type":"patent","source":"MLex","summary":"In patent clash with Xarelto-maker Bayer, Mylan’s PTAB win called into question - MLex","headline":"In patent clash with Xarelto-maker Bayer, Mylan’s PTAB win called into question","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxOQkxYaTJGM1oySFpndVdSMmpiS2g4SERhUVduNmxTU1MwaUxkc3ZoYkI2cGxTeExPQVVrOFdVbjVVaVFqY1IzRnI4Wkw0ZUR1YXBYYWhmVzZPM1A0dG1vUUNSQTlQSEE1NE5NNHpIYUJfMWhvV2huRXZxY0lqRlFlZmpXOEVDT0FWM3lYcWZiWF9FeWJOck1GQTVDcUxfZlA2Tm1pR1pkRmh5X3N4VEVYOTJuXzloS1o5UXA1MWhOX1RfNDFBMHRqUVFLdw?oc=5","date":"2025-04-07","type":"pipeline","source":"NCDOJ (.gov)","summary":"Attorney General Jeff Jackson Wins up to $335 Million from Pharmaceutical Company Mylan for Fueling Opioid Crisis - NCDOJ (.gov)","headline":"Attorney General Jeff Jackson Wins up to $335 Million from Pharmaceutical Company Mylan for Fueling Opioid Crisis - NCDO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQZUlIRUhQdll1aVk2c3FIbUFjaHFuMzVJS1MydFg5YUZMb01wQk1sVmJtd19pRWtLZTBMdmw2d3hFMVZTdHg1Y2JWUzVKYVQtRUhmMUxxUUdZaWx4VWVOWUk5OFo1b3J6THNTTWhJZEdpeWFESkdNT1p4aElfZmNaQkdLTlU3bmJ0Y08weE1nQ1lZSS1wd3NZaXNCT1lhbVktYktSYjF0allRbU5nSHk4OVItd0liV2xxa092RklLY2tsUTlf?oc=5","date":"2025-04-07","type":"pipeline","source":"Delawareonline.com","summary":"Delaware will receive portion of $335M settlement with opioid manufacturer Mylan Inc. - Delawareonline.com","headline":"Delaware will receive portion of $335M settlement with opioid manufacturer Mylan Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQT1FIQ3F4WU5Jb2Z6aElaR2tLYk1sbHpseldjZ3BtMm1wcDg2N0pLdlVTUjg3cWZhemF5SGN0S3FuRE9kMlhmRV9WVlcxci12LVh3UVFZOU95a2RGZGdxY3F0U2l4c18zbkNjVjhkdEY1VmczVnczSTRKeC1pUk95VXVKM0NVdVlfSDFHNHZKaHM4VTNGZVhfOWdLNTQ0QVRJWnpHUVY1Mk0?oc=5","date":"2021-08-10","type":"pipeline","source":"Mountain State Spotlight","summary":"Morgantown pharmaceutical plant’s fall started long ago - Mountain State Spotlight","headline":"Morgantown pharmaceutical plant’s fall started long ago","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxQcmd5NTdIQWZadFpieXh1OTNENS1QcTBfaVozSjk1STFWSjVuV2h4YnIwZDF3akFNakc4WDVpaVQzZC1LS0YxZldLTERXR0hWS0VyMzJMQkNzbENIUi05b2VPcjBXRGNJcGN3eVE4MWpWb3VUYUhRVEtNc2t0SW1BTDdHcVBlbE1RWmpadVo5anZpODBLNFVZTl9hNEI0MUJ1b3ZXMUpobVVRSTJ5R0owVHBBcDV3VGo4SGJ0ekNnS0pDYVlDYkU0QTFwdDR0T0xpcFExMXJQSldfVFBIemw2SlBUYS1DNm5kSEZ6TlZkaktCblR1QjZSX0pkZW5WMVNRamU0Znpwd0FpeC1zbi16WXNVdHBfOUNmazJldHpFYkRmRUdpSEItWnZLV0daUQ?oc=5","date":"2020-05-21","type":"pipeline","source":"Pfizer","summary":"Combining Upjohn and Mylan to Create a New Champion for Global Health - Pfizer","headline":"Combining Upjohn and Mylan to Create a New Champion for Global Health","sentiment":"neutral"}],"patents":[],"drugCount":55,"phaseCounts":{"marketed":20,"phase_3":20,"phase_1":14,"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":6796110000,"revenuePeriod":"2012-12-31","revenueHistory":[{"value":6796110000,"period":"2012-12-31"},{"value":6129825000,"period":"2011-12-31"},{"value":6129825000,"period":"2011-12-31"},{"value":5450522000,"period":"2010-12-31"},{"value":5450522000,"period":"2010-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":581800000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":640850000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":15886600000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}